platelet-rich plasma + peripheral blood mononuclear cells

Platelet-rich plasma + peripheral blood mononuclear cells is an autologous regenerative combination product that pairs **platelet-rich plasma** with **peripheral blood mononuclear cells** for local administration, typically by injection into injured or degenerating tissue. The therapeutic rationale is not based on a single defined molecular target, but on the combined delivery of platelet-derived growth factors, cytokines, chemokines, and viable mononuclear immune cells that may modulate inflammation, promote tissue repair, enhance angiogenic and stromal signaling, and in some settings bias macrophage responses toward a reparative phenotype. Reported clinical and translational use has been exploratory rather than standardized, with published examples including intraovarian administration for diminished ovarian reserve and intradiscal use in discogenic low back pain and intervertebral disc degeneration. This is best viewed as a procedure-based, patient-specific biologic combination therapy in regenerative medicine rather than a conventional pharmaceutical drug with a fixed composition, manufacturer, or universally established mechanism.

Other names

platelet-rich plasma + peripheral blood mononuclear cellsPRP + PBMCsplatelet-rich plasma + PBMCsautologous platelet-rich plasma combined with peripheral blood mononuclear cells